845 related articles for article (PubMed ID: 32043791)
1. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups.
Macchia G; Nardangeli A; Laliscia C; Fodor A; Draghini L; Gentile PC; D'Agostino GR; Balcet V; Bonome P; Ferioli M; Autorino R; Vicenzi L; Raguso A; Borghesi S; Ippolito E; Di Cataldo V; Cilla S; Perrucci E; Campitelli M; Gambacorta MA; Deodato F; Scambia G; Ferrandina G
Int J Gynecol Cancer; 2022 Jun; 32(6):732-739. PubMed ID: 35193941
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups.
Macchia G; Pezzulla D; Campitelli M; Laliscia C; Fodor A; Bonome P; Draghini L; Ippolito E; De Sanctis V; Ferioli M; Titone F; Balcet V; Di Cataldo V; Russo D; Vicenzi L; Cossa S; Lucci S; Cilla S; Deodato F; Gambacorta MA; Scambia G; Morganti AG; Ferrandina G
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):321-332. PubMed ID: 37150261
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD).
Macchia G; Jereczek-Fossa BA; Lazzari R; Cerrotta A; Deodato F; Ippolito E; Aristei C; Gambacorta MA; Scambia G; Valentini V; Ferrandina G
Int J Gynecol Cancer; 2022 Jul; 32(7):939-943. PubMed ID: 34155084
[TBL] [Abstract][Full Text] [Related]
5. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Sterotactic Body Radiotherapy (SBRT) for pelvic lymph node recurrences after adjuvant or primary radiotherapy for prostate cancer.
Gamsiz H; Sager O; Uysal B; Dincoglan F; Demiral S; Ozcan F; Colak O; Dirican B; Beyzadeoglu M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S851-S856. PubMed ID: 38384065
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
Ingrosso G; Trippa F; Maranzano E; Carosi A; Ponti E; Arcidiacono F; Draghini L; Di Murro L; Lancia A; Santoni R
World J Urol; 2017 Jan; 35(1):45-49. PubMed ID: 27233779
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).
Park HJ; Chang AR; Seo Y; Cho CK; Jang WI; Kim MS; Choi C
Anticancer Res; 2015 Sep; 35(9):5103-10. PubMed ID: 26254414
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
14. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.
Zhao X; Zhu X; Fei J; Ren H; Cao Y; Ju X; Yuan Z; Zhang H
Radiat Oncol; 2018 Oct; 13(1):205. PubMed ID: 30348187
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy for Pulmonary Oligometastasis from Colorectal Cancer.
Kobayashi N; Abe T; Noda SE; Kumazaki YU; Hirai R; Igari M; Aoshika T; Saito S; Ryuno Y; Kato S
In Vivo; 2020; 34(5):2991-2996. PubMed ID: 32871842
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Reshko LB; Baliga S; Crandley EF; Harry Lomas IV; Richardson MK; Spencer K; Bennion N; Mikdachi HE; Irvin W; Kersh CR
Gynecol Oncol; 2020 Dec; 159(3):611-617. PubMed ID: 33059914
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment.
Shen J; Tao Y; He L; Guan H; Zhen H; Liu Z; Zhang F
Discov Oncol; 2022 Aug; 13(1):82. PubMed ID: 36006491
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
